On August 28, 2026, the FDA approved Moderna's mNEXSPIKE vaccine and gave the green light to Novavax's Nuvaxovid vaccine. Separately, ProFound Therapeutics was formed by Flagship Pioneering.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
On August 28, 2026, the FDA approved Moderna's mNEXSPIKE vaccine and gave the green light to Novavax's Nuvaxovid vaccine. Separately, ProFound Therapeutics was formed by Flagship Pioneering.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- Nasdaq added Moderna to its Nasdaq-100 index, and Moderna combined its vaccine with Merck's drug.
- Moderna's stock gains are being driven by FDA approval and the broader growth of AI businesses, as a Nasdaq constituent.